Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money

71% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

5 Top Stories

ARK’s AI choices; Getty partners with Nvidia; Novo Nordisk’s AI programme

Every day, we handpick the 5 Top Stories stock market investors need to know. In 5 minutes, you’ll learn the stocks, CEOs, and money managers moving markets.

Which AI Stocks Does ARK Prefer to Nvidia?

Nvidia [NVDA] has seen its share price leap by more than 180% this year. Despite — or because of — this, ARK’s Cathie Wood has said there are more interesting artificial intelligence (AI) stocks on the market. “Nvidia’s easy, but it’s also really expensive and very obvious,” said Wood at an investor conference in Munich. Wood named UiPath [PATH] and Twilio [TWLO] as more interesting alternatives, in particular highlighting the potential of UiPath’s platform: “It’s not sexy, but it’s very profitable.

Getty Partners with Nvidia on AI Tool

With a view to generating AI content that avoids copyright issues, Getty Images [GETY] is working with Nvidia on an AI tool that will create images using the firm’s library of millions of photos. However, the new tool will not draw on Getty’s bank of news photos, in order to militate against deepfakes. Elsewhere, French billionaire Xavier Niel is to invest €200m in an AI research lab powered by Nvidia, as well as funding start-ups in the field.

Novo Nordisk’s $2.7bn AI Programme

Having become Europe’s most valuable company off the back of the success of its weight-loss blockbuster Wegovy, Denmark’s Novo Nordisk [NOVO-B.CO] is to partner with US tech firm Valo Health on the use of AI to develop new drugs. The deal — which could be worth up to $2.7bn, according to Bloomberg — will see the two firms collaborate on 11 programmes, focused on heart and metabolic conditions.  

Alibaba Set to List Cainiao in Hong Kong

The Chinese e-commerce behemoth announced Tuesday that it plans to spin off its logistics unit Cainiao on the Hong Kong Stock Exchange. In a regulatory filing, Alibaba [9988.HK] said it would hold more than 50% of the shares in the unit following the listing. Cainiao will be the first of six units that Alibaba has slated for potential IPOs, although Alibaba has underlined that there is “no assurance” that the spin-off will go ahead.  

Tesla Under EU Scrutiny

Tesla [TSLA] shares opened 1.6% down on Tuesday following news that the firm was in the sights of the EU’s anti-subsidy probe into Chinese electric vehicles (EVs). Tesla sold some 93,700 made-in-China EVs in Western Europe in the first seven months of 2023, Bloomberg reported. Meanwhile, Nissan [7201.T] announced that all its new EU models will be fully electric, and by 2030 it will only be selling EVs in Europe. “There is no turning back now,” said CEO Makoto Uchida in a statement.

Disclaimer Past performance is not a reliable indicator of future results.

CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.

CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.

Continue reading for FREE

Latest articles